Cingulate received a Complete Response Letter from the FDA shortly after the May 31, 2026 PDUFA target date for its CTx-1301 NDA under the 505(b)(2) pathway, signaling that the application in its current form was not approved due to unresolved manufacturing, chemistry, or controls issues. Traders have priced this outcome at near-certainty because the agency action directly followed the review timeline, consistent with standard regulatory practice when additional data or responses are required. While the company continues engaging the FDA and maintains cash runway into 2027 for potential resubmission, approval remains contingent on addressing the CRL specifics, with no guaranteed timeline or outcome.